John D. Bradley
Managing Director
New York Office | john.bradley@torreya.com | 212.257.5805
John Bradley, a Managing Director at Torreya, works with the firm’s financing and M&A businesses. John has a vast network of relationships in the life sciences industry, as well as with family offices and high net worth individuals worldwide. An expert in branded pharmaceuticals and drug delivery, he has raised over $500 million in public and private capital for many pharmaceutical, insurance, and technology companies.
John has more than 40 years of corporate finance experience as an executive within both pharmaceutical companies and investment banks. He has also managed the assets of several large family offices.
His career highlights prior to joining Torreya in 2008 include Co-Founder and Chairman of the Board of Mystic Pharmaceuticals; Founder and Chairman of VentureLink; early-stage financings of many pharmaceutical companies, including Watson Pharmaceuticals (now part of Allergan Pharma), Ethical Holdings, Ltd., Caraco Pharmaceuticals (now part of Sun Pharma), and Lemmon Pharmacal, Inc. (now part of Teva Pharmaceuticals, Inc.); and President and Founder of Bradley-Hummel & Co., Inc., a NYSE member firm. Earlier in his career, he held positions at Brown Brothers Harriman and Drexel Burnham Lambert & Co.
John is a senior advisor to the New York Center for Living – Rehabilitation Center for Adolescents and Young Adults.
Selected Transactions
|
| Credit facility from |
|
|
$70 million
January 2019
|
|
| Sale of majority equity stake to |
|
|
Undisclosed
December 2017
|
|
| Sale of equity stake to |
|
|
$33 million
November 2016
|
|
| Advisory to ownership group on sale to |
|
|
Undisclosed
March 2016
|
|
| Senior term loan |
|
|
$15 million
December 2015
|
|
| Majority recap by |
|
|
Undisclosed
March 2018
|
|
| Preferred equity investment |
|
|
|
$7 million
January 2016
|
|
| Merger into |
|
|
Undisclosed
September 2013
|
|
| Sale for up to $106 million to |
|
|
$12 million +
milestones January 2013
|